SeaStar Medical Holding Corporation (ICU)
NASDAQ: ICU · IEX Real-Time Price · USD
8.80
+0.91 (11.53%)
At close: Jul 26, 2024, 4:00 PM
9.15
+0.35 (3.98%)
After-hours: Jul 26, 2024, 7:35 PM EDT
Company Description
SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States.
The company offers inflammatory response to fend off infections and repair damaged tissue in the body.
It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome.
The company is headquartered in Denver, Colorado.
SeaStar Medical Holding Corporation
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Eric Schlorff |
Contact Details
Address: 3513 Brighton Blvd, Suite 410 Denver, Colorado 80216 United States | |
| Phone | 844-427-8100 |
| Website | seastarmedical.com |
Stock Details
| Ticker Symbol | ICU |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001831868 |
| CUSIP Number | 81256L104 |
| ISIN Number | US81256L1044 |
| Employer ID | 85-3681132 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Eric Schlorff | Chief Executive Officer, President and Executive Director |
| Dr. H. David Humes M.D. | Co-Founder and Managing Director |
| Colonel Kevin Chung FACP, M.D. | Chief Medical Officer |
| David A. Green CPA, M.B.A. | Chief Financial Officer |
| Tom Mullen | Vice President of Operations and Product Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 26, 2024 | D | Notice of Exempt Offering of Securities |
| Jul 11, 2024 | 8-K | Current Report |
| Jul 11, 2024 | 424B5 | Filing |
| Jul 9, 2024 | 8-K | Current Report |
| Jul 5, 2024 | 8-K | Current Report |
| Jul 3, 2024 | 10-K/A | [Amend] Annual report |
| Jul 3, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Jul 2, 2024 | 8-K | Current Report |
| Jun 28, 2024 | 8-K | Current Report |
| Jun 11, 2024 | 8-K | Current Report |